| Japanese |
|---|
| Title | PhenobarbitalおよびDiphenylhydantoin同時測定によるヒダントールF投与量の検討 |
|---|
| Subtitle | 短報 |
|---|
| Authors | 山田英夫*, 村木俊夫**, 布施正明***, 丹野宗彦* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京都老人医療センター核医学放射線部, **杏林大学医学部第三内科, ***東京都老人医療センター脳神経外科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 24 |
|---|
| Number | 10 |
|---|
| Page | 1557-1559 |
|---|
| Year/Month | 1987/10 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. 緒言」 脳疾患の術後, 脳血管障害後のLATE SEIZUREにおいては, 抗痙攣剤が用いられる. この目的のために当センターの脳外科においては, 一般にフェノバルビタール (PB) とディフェニルヒダントイン (DPH) の合剤であるヒダントールFが用いられている. この薬剤の成人一般における投与量は, 一日12錠である. しかし高齢者においては少ない投与量にもかかわらず精神機能の低下や嗜眠傾向が現れることが経験される. その原因を検討するために両剤の血中濃度を測定した. 「II. 方法および対象」 当センター脳外科において手術後ヒダントールFを連続的に投与されている患者, 男18例 (平均62.8歳) , 女12例 (平均69.8歳) についてRADIOIMMUNOASSAYによりPBとDPHの血中濃度を測定した. RADIOIMMUNOASSAYはGamma Coat I-125 phenobarbitalおよびGamma Coat I-125 Phenytoinにて行った. ヒダントールF投与量は一日当たり3-12錠であった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Radioimmunoassay, Phenobarbital, Diphenylhydantoin, Untoward effect |
|---|
| English |
|---|
| Title | Studies on Dosage of HIDANTOL-F by Simultaneous Determination of Serum Phenobarbital and Diphenylhydantoin |
|---|
| Subtitle | |
|---|
| Authors | Hideo YAMADA*, Toshio MURAKI**, Masaaki FUSE***, Munehiko TANNO* |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine and Radiological Science, Tokyo Metropolitan Geriatric Hospital, **Third Internal Medicine, Department of Medicine, Kyourin University, ***Department of Brain Surgery, Tokyo Metropolitan Geriatric Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 24 |
|---|
| Number | 10 |
|---|
| Page | 1557-1559 |
|---|
| Year/Month | 1987/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] In order to investigate causes of untoward effects frequently observed in elderly patients on HIDANTOL-F which contains 300 mg of phenobarbital (PB) , 100 mg of diphenylhydantoin (DPH) and 200 mg of Na benzoate-caffein, blood levels of both PB and DPH were measured by radioimmunoassay. About half of the patients showed blood levels of PB distributed in therapeutic range, some of which were very cross to toxic range. None of the blood samples except one, however, was in therapeutic range in regard to DPH. There was some degree of correlation between blood levels of these two drugs (r=0.53) . Absolute doses of PB and blood levels showed linear relationship, while DPH was curvelinear in shape in regard to doseblood level relation, suggestive of Michaelis-Menten pharmacokinetics. Taking account of blood levels of these two drugs in the present study, phenobarbital must be responsible for untoward effects of HIDANTOL-F as well as anticonvulsive effect. Synergistic effect and mutual influences over pharmacokinetics of PB and DPH were discussed. Ratio of several drugs in case of combination therapy should be determined on the basis of study on pharmacokinetics and interaction of drugs. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Radioimmunoassay, Phenobarbital, Diphenylhydantoin, Untoward effect |
|---|